AU2001233081A1 - Composition for treatment of stress - Google Patents

Composition for treatment of stress

Info

Publication number
AU2001233081A1
AU2001233081A1 AU2001233081A AU3308101A AU2001233081A1 AU 2001233081 A1 AU2001233081 A1 AU 2001233081A1 AU 2001233081 A AU2001233081 A AU 2001233081A AU 3308101 A AU3308101 A AU 3308101A AU 2001233081 A1 AU2001233081 A1 AU 2001233081A1
Authority
AU
Australia
Prior art keywords
stress
treatment
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001233081A
Inventor
Judith J. Wurtman
Richard J. Wurtman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of AU2001233081A1 publication Critical patent/AU2001233081A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AU2001233081A 2000-01-27 2001-01-29 Composition for treatment of stress Abandoned AU2001233081A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09492110 2000-01-27
US09/492,110 US6579899B1 (en) 1998-07-16 2000-01-27 Composition for treatment of stress
PCT/US2001/002854 WO2001054681A2 (en) 2000-01-27 2001-01-29 Composition for treatment of stress

Publications (1)

Publication Number Publication Date
AU2001233081A1 true AU2001233081A1 (en) 2001-08-07

Family

ID=23954978

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001233081A Abandoned AU2001233081A1 (en) 2000-01-27 2001-01-29 Composition for treatment of stress

Country Status (6)

Country Link
US (1) US6579899B1 (en)
EP (1) EP1253915A1 (en)
JP (1) JP2003521498A (en)
AU (1) AU2001233081A1 (en)
CA (1) CA2398821A1 (en)
WO (1) WO2001054681A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (en) 1999-07-08 2002-06-12 Lundbeck & Co As H TREATMENT OF NEUROTIC DISORDERS
EP1266659A1 (en) * 2001-06-11 2002-12-18 Pantarhei Bioscience B.V. Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes
WO2003013495A1 (en) * 2001-08-08 2003-02-20 Smothers Don L Formulation and method for reduction of stress in meat-producing animals
JP2003081829A (en) * 2001-09-13 2003-03-19 Ajinomoto Co Inc Circadian rhythm regulator
AU2002243097A1 (en) * 2002-04-03 2003-10-13 Hyundai Pharm. Ind. Co., Ltd. Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same
US20040001817A1 (en) * 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
TW200402289A (en) * 2002-05-17 2004-02-16 Wyeth Corp Methods of treating gastrointestinary and genitourinary pain disorders
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2005112906A2 (en) * 2004-05-21 2005-12-01 Duke University Method for augmenting the effects of serotonin reuptake inhibitors
WO2005123043A2 (en) * 2004-06-10 2005-12-29 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US20070117844A1 (en) * 2005-11-18 2007-05-24 Morillo Connie S 5-HTP combination therapy
US20070213370A1 (en) * 2005-11-18 2007-09-13 H. Lundbeck A/S 5-HTP Combination Therapy
WO2007064697A1 (en) 2005-12-01 2007-06-07 Auspex Pharmaceuticals, Inc. Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
US20080139510A1 (en) * 2006-12-07 2008-06-12 Abe Rose Treatment of migraine headaches with sublingual amino acids
US20080220104A1 (en) * 2007-03-08 2008-09-11 Cappello John V Compositions for producing satiety
WO2008140859A1 (en) 2007-03-15 2008-11-20 Auspex Pharmaceuticals, Inc. Deuterated venlafaxines and 0-desmetylvenlafaxines with serotoninergic and / or norepinephrinergic activity
KR20100014081A (en) * 2007-05-11 2010-02-10 하. 룬트벡 아크티에 셀스카브 5-htp combination therapy
US20090017136A1 (en) * 2007-07-10 2009-01-15 Wayne Gorsek Formulation to prevent and treat fibromyalgia, depression and other muscle and nervous system disorders
JP6041242B2 (en) * 2010-10-05 2016-12-07 ディーエスエム アイピー アセッツ ビー．ブイ． Peptides containing tryptophan
WO2012054815A1 (en) 2010-10-22 2012-04-26 Duke University Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
MX355027B (en) * 2012-11-02 2018-03-28 Dsm Ip Assets Bv Use of tryptophan rich protein hydrolysates.
US11352326B2 (en) 2016-11-16 2022-06-07 The General Hospital Corporation Myeloperoxidase imaging agents
EP3952864A4 (en) * 2019-03-08 2023-05-10 The Regents of the University of California Compositions and methods for modulating lipid and steroid metabolism
CN110776454B (en) * 2019-12-10 2021-03-23 马宏跃 Synthesis method of bufotenine and quaternary ammonium salt thereof and application of bufotenine and quaternary ammonium salt thereof in preparation of analgesic and anti-inflammatory drugs

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3198834A (en) 1964-07-27 1965-08-03 Snc Science Union Et Compagnie Optical isomers of trifluoromethylated phenethylamines
US4309445A (en) 1980-06-16 1982-01-05 Massachusetts Institute Of Technology d-Fenfluramine for modifying feeding behavior
US4452815A (en) * 1980-06-16 1984-06-05 Massachusetts Institute Of Technology Method of utilizing d,l-fenfluramine for modifying feeding behavior
NL8701682A (en) 1986-07-30 1988-02-16 Sandoz Ag METHOD FOR THE THERAPEUTIC USE OF SEROTONIN ANTAGONISTS, ACTIVE COMPOUNDS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
CA2117430A1 (en) 1992-02-21 1993-09-02 Richard Katz Brofaromine as an agent for treating post-traumatic stress
DK0639374T3 (en) 1993-06-28 2002-05-06 American Home Prod New methods of treatment using phenethyl derivatives
FR2710916B1 (en) 1993-10-04 1995-12-22 Pasteur Institut Compounds of a peptide nature having a modulating activity of the serotonergic response; diagnostic and therapeutic applications.
TW344661B (en) 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
US5502080A (en) 1994-11-01 1996-03-26 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of allergic disorders
US5658955A (en) * 1994-11-01 1997-08-19 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of immune disorders
US5885976A (en) * 1995-05-08 1999-03-23 Sandyk; Reuven Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions
US5716976A (en) * 1996-03-13 1998-02-10 Bernstein; Richard K. Method of treatment for carbohydrate addiction
US5852020A (en) 1996-11-22 1998-12-22 Bristol-Myers Squibb Company Nefazodone: use in treating post traumatic stress disorder

Also Published As

Publication number Publication date
WO2001054681A2 (en) 2001-08-02
WO2001054681A8 (en) 2002-01-17
CA2398821A1 (en) 2001-08-02
US6579899B1 (en) 2003-06-17
EP1253915A1 (en) 2002-11-06
JP2003521498A (en) 2003-07-15

Similar Documents

Publication Publication Date Title
AU2001233081A1 (en) Composition for treatment of stress
AU2001272849A1 (en) Composition for the treatment of osteoarthritis
AU2002257936A1 (en) Methods of well treatment
AU2001272852A1 (en) Composition for the treatment of migraine
AU2000276362A1 (en) Composition for the treatment of diabetes
AU2002243023A1 (en) Compositions for preventing and/or treating oral diseases
AU2002240359A1 (en) Pharmaceutical composition for the treatment of alopecia
AU2001286983A1 (en) Method of treatment
WO2001091700A8 (en) Composition and method for enhancing elasticity of tissue
AU2002231206A1 (en) Treatment of depression
AU1878201A (en) Composition for the treatment of damaged tissue
AU5179800A (en) Mycolactone and related compounds, compositions and methods of use
AU2001255730A1 (en) Methods and compositions for the treatment of cardiac indications
AU2001262177A1 (en) Method of treatment
AU2000231423A1 (en) Specific therapeutic composition for treating aids
EP1096927A4 (en) Composition for treatment of stress
AU2002349788A1 (en) Fiber treatment agent composition
AU2683500A (en) Compositions for the treatment of pain
AU2003240174A1 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
AU2001253560A1 (en) Methods of treatment
AU2002342188A1 (en) Methods and compositions for treating flavivirus-mediated disease
AU2001253903A1 (en) Compositions and methods for treatment of multiple myeloma
AU2001253219A1 (en) Composition for treatment of autoimmune disease
AU2002353915A1 (en) Methods and compositions for treating rotavirus-mediated disease
AUPQ662500A0 (en) Method of treatment